Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
**Background:** The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. The safety and efficacy of daratumumab regimens in the treatment of newly diagnosed MM (NDMM) is demonstrated in clinic...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-07-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.120288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860307306479616 |
|---|---|
| author | Anas Hamad Shereen Elazzazy Ruba Y. Taha Hani Osman Sana Alblooshi Islam Elkonaissi Mustaqeem A. Siddiqui Khalil Al-Farsi Mohammed Al Lamki Sali Emara Gihan H. Elsisi |
| author_facet | Anas Hamad Shereen Elazzazy Ruba Y. Taha Hani Osman Sana Alblooshi Islam Elkonaissi Mustaqeem A. Siddiqui Khalil Al-Farsi Mohammed Al Lamki Sali Emara Gihan H. Elsisi |
| author_sort | Anas Hamad |
| collection | DOAJ |
| description | **Background:** The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. The safety and efficacy of daratumumab regimens in the treatment of newly diagnosed MM (NDMM) is demonstrated in clinical trials.
**Objective:** To assess the financial effects of the adoption of subcutaneous daratumumab (dara-SC) rather than intravenous daratumumab (dara-IV) for the treatment of NDMM in three Gulf countries (Qatar, Oman and the United Arab Emirates; UAE), a cost-minimization model was constructed.
**Methods:** We performed static cost minimization analyses from a societal perspective to evaluate the costs and possible reductions in resource utilization associated with a shift from dara-IV infusion to dara-SC injection for NDMM patients over a 5-year time horizon. The model included 2 scenarios: the current scenario in which 100% of patients with NDMM are treated with dara-IV infusion and a future scenario in which dara-SC injection is gradually adopted over the modeled time horizon. The model differentiated precisely between autologous stem cell transplantation (ASCT)–eligible and ASCT-ineligible NDMM patients in terms of their number in each group and the associated therapeutic regimens. One-way sensitivity analyses were also conducted.
**Results:** The model showed that the use of dara-SC in NDMM patients who were eligible or ineligible for ASCT resulted in lower non-drug costs, including premedication drug costs, adverse-effect costs, administration costs, medical staff costs, and indirect costs. The resulting total savings over the 5-year time horizon of the model for Hamad Medical Corporation, Sultan Qaboos University Hospital/Royal Hospital, Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital were QAR −2 522 686, OMR −143 214, AED −30 010 627, and AED −5 003 471, respectively.
**Conclusion:** The introduction of dara-SC as a front-line treatment for NDMM patients in Qatar (Hamad Medical Corporation), Oman (Sultan Qaboos University Hospital, Royal Hospital-MOH), and the UAE (SSMC and Tawam Hospital) can help save resources and minimize constraints on the healthcare system. |
| format | Article |
| id | doaj-art-c074ae4a6c2d449aab47104937484464 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-c074ae4a6c2d449aab471049374844642025-02-10T16:13:37ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362024-07-01112Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf CountriesAnas HamadShereen ElazzazyRuba Y. TahaHani OsmanSana AlblooshiIslam ElkonaissiMustaqeem A. SiddiquiKhalil Al-FarsiMohammed Al LamkiSali EmaraGihan H. Elsisi**Background:** The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. The safety and efficacy of daratumumab regimens in the treatment of newly diagnosed MM (NDMM) is demonstrated in clinical trials. **Objective:** To assess the financial effects of the adoption of subcutaneous daratumumab (dara-SC) rather than intravenous daratumumab (dara-IV) for the treatment of NDMM in three Gulf countries (Qatar, Oman and the United Arab Emirates; UAE), a cost-minimization model was constructed. **Methods:** We performed static cost minimization analyses from a societal perspective to evaluate the costs and possible reductions in resource utilization associated with a shift from dara-IV infusion to dara-SC injection for NDMM patients over a 5-year time horizon. The model included 2 scenarios: the current scenario in which 100% of patients with NDMM are treated with dara-IV infusion and a future scenario in which dara-SC injection is gradually adopted over the modeled time horizon. The model differentiated precisely between autologous stem cell transplantation (ASCT)–eligible and ASCT-ineligible NDMM patients in terms of their number in each group and the associated therapeutic regimens. One-way sensitivity analyses were also conducted. **Results:** The model showed that the use of dara-SC in NDMM patients who were eligible or ineligible for ASCT resulted in lower non-drug costs, including premedication drug costs, adverse-effect costs, administration costs, medical staff costs, and indirect costs. The resulting total savings over the 5-year time horizon of the model for Hamad Medical Corporation, Sultan Qaboos University Hospital/Royal Hospital, Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital were QAR −2 522 686, OMR −143 214, AED −30 010 627, and AED −5 003 471, respectively. **Conclusion:** The introduction of dara-SC as a front-line treatment for NDMM patients in Qatar (Hamad Medical Corporation), Oman (Sultan Qaboos University Hospital, Royal Hospital-MOH), and the UAE (SSMC and Tawam Hospital) can help save resources and minimize constraints on the healthcare system.https://doi.org/10.36469/001c.120288 |
| spellingShingle | Anas Hamad Shereen Elazzazy Ruba Y. Taha Hani Osman Sana Alblooshi Islam Elkonaissi Mustaqeem A. Siddiqui Khalil Al-Farsi Mohammed Al Lamki Sali Emara Gihan H. Elsisi Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries Journal of Health Economics and Outcomes Research |
| title | Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries |
| title_full | Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries |
| title_fullStr | Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries |
| title_full_unstemmed | Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries |
| title_short | Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries |
| title_sort | cost minimization analysis for subcutaneous daratumumab in the treatment of newly diagnosed multiple myeloma in three gulf countries |
| url | https://doi.org/10.36469/001c.120288 |
| work_keys_str_mv | AT anashamad costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT shereenelazzazy costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT rubaytaha costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT haniosman costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT sanaalblooshi costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT islamelkonaissi costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT mustaqeemasiddiqui costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT khalilalfarsi costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT mohammedallamki costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT saliemara costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries AT gihanhelsisi costminimizationanalysisforsubcutaneousdaratumumabinthetreatmentofnewlydiagnosedmultiplemyelomainthreegulfcountries |